Paper35840985
Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma.
Wang Y and 8 others. World J Surg Oncol, 2022. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma. Papers, record 35840985. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35840985
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Esophageal Neoplasms | Major topic |
| Esophageal Squamous Cell Carcinoma | Major topic |
| Biomarkers, Tumor | |
| Computational Biology | |
| Gene Expression Regulation, Neoplastic | |
| Glucuronidase | |
| Humans | |
| Hypoxia | |
| Immunohistochemistry | |
| Prognosis | |
| Tumor Microenvironment | |
| Heparanase |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18273037 | Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18273037 | PubMed |
| 2 | 32375686 | Integrated analysis of genome-wide miRNAs and targeted gene expression in esophageal squamous cell carcinoma (ESCC) and relation to prognosis. | BMC Cancer | 2020 | https://conductscience.org/library/papers/32375686 | PubMed |
| 3 | 22952874 | Allele loss and down-regulation of heparanase gene are associated with the progression and poor prognosis of hepatocellular carcinoma. | PLoS One | 2012 | https://conductscience.org/library/papers/22952874 | PubMed |
| 4 | 11395850 | Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. | Semin Oncol | 2001 | https://conductscience.org/library/papers/11395850 | PubMed |
| 5 | 24862152 | Heparanase multiple effects in cancer. | Thromb Res | 2014 | https://conductscience.org/library/papers/24862152 | PubMed |
| 6 | 17891338 | A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. | Invest New Drugs | 2008 | https://conductscience.org/library/papers/17891338 | PubMed |
| 7 | 16901744 | Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. | Int J Biochem Cell Biol | 2006 | https://conductscience.org/library/papers/16901744 | PubMed |
| 8 | 8707262 | Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. | Hepatology | 1996 | https://conductscience.org/library/papers/8707262 | PubMed |
| 9 | 19303160 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. | J Hepatol | 2009 | https://conductscience.org/library/papers/19303160 | PubMed |
| 10 | 29145629 | The Reactome Pathway Knowledgebase. | Nucleic Acids Res | 2018 | https://conductscience.org/library/papers/29145629 | PubMed |
| 11 | 31166985 | Understanding heterogeneous tumor microenvironment in metastatic melanoma. | PLoS One | 2019 | https://conductscience.org/library/papers/31166985 | PubMed |
| 12 | 22507220 | Epidemiologic differences in esophageal cancer between Asian and Western populations. | Chin J Cancer | 2012 | https://conductscience.org/library/papers/22507220 | PubMed |
| 13 | 32820608 | GSVA score reveals molecular signatures from transcriptomes for biomaterials comparison. | J Biomed Mater Res A | 2021 | https://conductscience.org/library/papers/32820608 | PubMed |
| 14 | 29290801 | RHCG Suppresses Tumorigenicity and Metastasis in Esophageal Squamous Cell Carcinoma via Inhibiting NF-κB Signaling and MMP1 Expression. | Theranostics | 2018 | https://conductscience.org/library/papers/29290801 | PubMed |
| 15 | 17440684 | Hypoxia in cancer: significance and impact on clinical outcome. | Cancer Metastasis Rev | 2007 | https://conductscience.org/library/papers/17440684 | PubMed |
| 16 | 33092083 | A Methylation-Based Reclassification of Bladder Cancer Based on Immune Cell Genes. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33092083 | PubMed |
| 17 | 26409826 | Integrative genomics analysis of genes with biallelic loss and its relation to the expression of mRNA and micro-RNA in esophageal squamous cell carcinoma. | BMC Genomics | 2015 | https://conductscience.org/library/papers/26409826 | PubMed |
| 18 | 24522499 | LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. | Gut | 2014 | https://conductscience.org/library/papers/24522499 | PubMed |
| 19 | 28536608 | Nuclear expression of TCF4/TCF7L2 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. | Cell Mol Biol Lett | 2016 | https://conductscience.org/library/papers/28536608 | PubMed |
| 20 | 8813149 | Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. | Cancer Res | 1996 | https://conductscience.org/library/papers/8813149 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40059241 | Identification of biomarkers and potential drug targets for esophageal cancer: a Mendelian randomization study. | Sci Rep | 2025 | https://conductscience.org/library/papers/40059241 | PubMed |
| 39248214 | Analysis of Expression Pattern and Prognostic Value of the Heparanase in Breast Cancer Through CD274/CTLA-4 Immune Checkpoint Proteins. | Technol Cancer Res Treat | 2024 | https://conductscience.org/library/papers/39248214 | PubMed |
| 36817484 | Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma. | Front Immunol | 2023 | https://conductscience.org/library/papers/36817484 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35840985
GET https://conductscience.org/api/papers/v1/35840985/references?page=2